4.6 Article

DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

Journal

PLOS GENETICS
Volume 10, Issue 4, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pgen.1004256

Keywords

-

Funding

  1. Mutua Madrilena Foundation (FMMA)
  2. Spanish Association against Cancer [AECC08]
  3. RTICC [06/0020/1060]
  4. European Community [223175 (HEALTH-F2-2009-223175)]
  5. Cancer Research UK [C1287/A10118, C1287/A 10710, C12292/A11174, C5047/A8384, C5047/A15007, C5047/A10692, C1287/A11990, C5047/A8385]
  6. National Institutes of Health [CA128978]
  7. Post-Cancer GWAS initiative [1 U19 CA 148537]
  8. Department of Defence [W81XWH-10-1-0341]
  9. Canadian Institutes of Health Research (CIHR)
  10. Komen Foundation for the Cure
  11. Breast Cancer Research Foundation
  12. Ovarian Cancer Research Fund
  13. Swedish Cancer Society
  14. Cancer Association of South Africa (CANSA)
  15. NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA125183, R01 CA142996, 1U01CA161032, CA116201]
  16. Ralph and Marion Falk Medical Research Trust
  17. Entertainment Industry Fund National Women's Cancer Research Alliance
  18. Basser Research Center
  19. American Cancer Society Early Detection Professorship [SIOP-06-258-01-COUN]
  20. National Cancer Institute [UM1 CA164920, CA 27469, CA 101165, CA 37517]
  21. Lithuania (BFBOCC-LT): Research Council of Lithuania [LIG-07/2012]
  22. Hereditary Cancer Association (Paveldimo vezio asociacija)
  23. LSC [10.0010.08]
  24. ESF [2009/0220/1DP/1.1.1.2.0/09/APIA/VIAA/016]
  25. Liepaja's municipal council
  26. Morris and Horowitz Families Professorship
  27. NEYE Foundation
  28. City of Hope Clinical Cancer Genetics Community Research Network, National Cancer Institute [RC4A153828]
  29. Office of the Director, National Institutes of Health
  30. Italian Association for Cancer Research (AIRC)
  31. FiorGen Foundation for Pharmacogenomics
  32. Associazione CAOS Varese
  33. European Union (European Social Fund - ESF)
  34. Greek national funds through the Operational Program Education and Lifelong Learning of the National Strategic Reference Framework (NSRF) - Research Funding Program of the General Secretariat for Research & Technology: ARISTEIA
  35. NIHR
  36. University of Kansas Cancer Center [P30 CA168524]
  37. Kansas Bioscience Authority Eminent Scholar Program
  38. Chancellors Distinguished Chair in Biomedical Sciences Professorship
  39. German Cancer Aid [109076]
  40. Center for Molecular Medicine Cologne (CMMC)
  41. Ligue National Contre le Cancer
  42. Association Le cancer du sein, parlons-en! Award
  43. Canadian Institutes of Health Research for the CIHR Team in Familial Risks of Breast Cancer program
  44. Intramural Research Program, NCI
  45. RTICC (ISCIII), Spanish Ministry of Economy and Competitivity [RD06/0020/0021]
  46. Helsinki University Central Hospital Research Fund
  47. Academy of Finland [132473]
  48. Finnish Cancer Society
  49. Sigrid Juselius Foundation
  50. Dutch Cancer Society [NKI1998-1854, NKI2004-3088, NKI2007-3756]
  51. Netherlands Organization of Scientific Research [NWO 91109024]
  52. Pink Ribbon grant [110005]
  53. BBMRI [NWO 184.021.007/CP46]
  54. Hungarian Research Grant KTIA-OTKA [CK-80745]
  55. Polish Foundation of Science
  56. Nordic Cancer Union, Icelandic Association Walking for Breast Cancer Research
  57. Landspitali University Hospital Research Fund
  58. Canadian Institutes of Health Research
  59. Canadian Breast Cancer Research Alliance-grant [019511]
  60. Ministry of Economic Development, Innovation and Export Trade [PSR-SIIRI-701]
  61. Ministero dell'Istruzione, dell'Universitae della Ricerca and Ministero della Salute
  62. National Breast Cancer Foundation
  63. National Health and Medical Research Council (NHMRC)
  64. Queensland Cancer Fund
  65. Cancer Councils of New South Wales, Victoria
  66. NIH [CA128978]
  67. U.S. Department of Defence Ovarian Cancer Idea award [W81XWH-10-1-0341]
  68. Sharon Levine Corzine Fund
  69. Niehaus Clinical Cancer Genetics Initiative
  70. Andrew Sabin Family Foundation
  71. Lymphoma Foundation
  72. US National Cancer Institute, NIH
  73. Westat, Inc, Rockville, MD [NO2-CP-11019-50, N02-CP-65504]
  74. Clalit Health Services in Israel
  75. Israel Cancer Association
  76. Breast Cancer Research Foundation (BCRF), NY
  77. Ohio State University Comprehensive Cancer Center
  78. [FISPI12/00070]
  79. [5U01CA113916]
  80. [R01CA140323]
  81. Cancer Research UK [17528, 11174, 11022, 16563, 10118, 17523, 15007] Funding Source: researchfish
  82. National Breast Cancer Foundation [IF-12-06] Funding Source: researchfish
  83. National Institute for Health Research [NF-SI-0510-10096] Funding Source: researchfish

Ask authors/readers for more resources

Single Nucleotide Polymorphisms (SNPs) in genes involved in the DNA Base Excision Repair (BER) pathway could be associated with cancer risk in carriers of mutations in the high-penetrance susceptibility genes BRCA1 and BRCA2, given the relation of synthetic lethality that exists between one of the components of the BER pathway, PARP1 (poly ADP ribose polymerase), and both BRCA1 and BRCA2. In the present study, we have performed a comprehensive analysis of 18 genes involved in BER using a tagging SNP approach in a large series of BRCA1 and BRCA2 mutation carriers. 144 SNPs were analyzed in a two stage study involving 23,463 carriers from the CIMBA consortium (the Consortium of Investigators of Modifiers of BRCA1 and BRCA2). Eleven SNPs showed evidence of association with breast and/or ovarian cancer at p<0.05 in the combined analysis. Four of the five genes for which strongest evidence of association was observed were DNA glycosylases. The strongest evidence was for rs1466785 in the NEIL2 (endonuclease VIII-like 2) gene (HR: 1.09, 95% CI (1.03-1.16), p = 2.7x10(-3)) for association with breast cancer risk in BRCA2 mutation carriers, and rs2304277 in the OGG1 (8-guanine DNA glycosylase) gene, with ovarian cancer risk in BRCA1 mutation carriers (HR: 1.12 95% CI: 1.03-1.21, p = 4.8x10(-3)). DNA glycosylases involved in the first steps of the BER pathway may be associated with cancer risk in BRCA1/2 mutation carriers and should be more comprehensively studied.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available